A METHOD OF DIFFERENTIATING AN INDUCED PLURIPOTENT STEM CELL INTO A RETINAL PIGMENT EPITHELIAL CELL, A RETINAL PIGMENT EPITHELIAL CELL AND METHODS OF USING THE RETINAL PIGMENT EPITHELIAL CELL
Agency for Science, Technology and Research (Singapore)
CellResearch Corporation Pte. Ltd (Singapore)
Singapore Health Services Pte Ltd (Singapore)
Inventor
Su, Xinyi
Kakkad, Regha
Bhargava, Mayuri
Yang, Binxia
Hunziker, Walter
Liu, Zengping
Wang, Haofei
Parikh, Bhav Harshad
Chen, Qingfeng
Lai, Fritz Shien Choong
Chai, Chou
Lim, Kah Leong
Phan, Toan Thang
Abstract
The present invention relates to a method of differentiating an induced pluripotent stem cell into a retinal pigment epithelial cell. Additionally, the present invention relates to a retinal pigment epithelial cell culture obtainable by the differentiation method and a retinal pigment epithelial cell culture obtained by the differentiation method. In addition, the present invention concerns a retinal pigment epithelium consisting of or comprising a retinal pigment epithelial cell culture obtainable or obtained by the differentiation method. The present invention also relates to a pharmaceutical composition comprising a retinal pigment epithelial cell culture obtained by the differentiation method. The present invention concerns a method of treating a retinal degenerative disease in a subject, comprising administering to a subject a retinal pigment epithelial cell differentiated from the induced pluripotent stem cell by the method. Finally, the present invention also refers to an in vivo method of detecting the survival rate of a retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in a subject and an in vitro method of determining the immunogenicity of said retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in said subject, to whom said differentiated RPE cell has been pre-delivered.
USE OF CONDITIONED MEDIUM OF CORD LINING MESENCHYMAL STEM CELLS FOR HEALING AND/OR PREVENTING THE FORMATION AND/OR RECURRENCE OF A WOUND OR A DAMAGED SKIN AREA
The invention also refers to a method of inducing, stimulating and/or promoting healing of a wound or a damaged skin area, wherein the method comprises topically treating the skin of a subject surrounding the wound or damaged skin area with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. Equally, the invention relates to a method of preventing formation and/or recurrence of a wound or a damaged skin area in a subject being at risk of developing a wound or a damaged skin area, wherein the method comprises topically treating the skin of the subject with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. Further, the invention relates to a method of treating rosacea, psoriasis, eczema, dermatitis, topical steroid withdrawal syndrome, epidermolysis bullosa, or skin damage caused by fragile skin, wherein the method comprises topically treating the skin of a subject surrounding the wound or damaged skin area to be treated with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. The present invention is also directed to conditioned medium, uses thereof, compositions comprising the same, methods of producing the same as well as uses of these compositions.
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
3.
USE OF CONDITIONED MEDIUM DERIVED FROM CULTIVATION OF MESENCHYMAL STEM CELLS OF THE UMBILICAL CORD FOR INDUCING, STIMULATING AND PROMOTING HAIR GROWTH AND REGENERATION
The present invention relates to a method of inducing, stimulating and/or promoting hair growth and/or hair regeneration, wherein the method comprises treating the hair of a subject with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. The present invention also relates to a method of alleviating and/or reducing hair loss and/or hair thinning, wherein the method comprises treating the hair a subject with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. The invention also relates to a method of producing a conditioned medium, the method comprising a) cultivating mesenchymal stem cells of the umbilical cord in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum); (b) removing the mesenchymal stem cells of the umbilical cord from the culture medium; wherein the conditioned medium is obtained by collecting the cell culture medium. The invention also relates to a conditioned medium obtained or obtainable by the producing method, a composition thereof and uses thereof.
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
4.
USE OF CONDITIONED MEDIUM DERIVED FROM CULTIVATION OF MESENCHYMAL STEM CELLS OF THE UMBILICAL CORD FOR INDUCING, STIMULATING AND PROMOTING HAIR GROWTH AND REGENERATION
The present invention relates to a method of inducing, stimulating and/or promoting hair growth and/or hair regeneration, wherein the method comprises treating the hair of a subject with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. The present invention also relates to a method of alleviating and/or reducing hair loss and/or hair thinning, wherein the method comprises treating the hair a subject with conditioned medium derived from cultivation of mesenchymal stem cells of the umbilical cord. The invention also relates to a method of producing a conditioned medium, the method comprising : a) cultivating mesenchymal stem cells of the umbilical cord in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum); b) removing the mesenchymal stem cells of the umbilical cord from the culture medium; wherein the conditioned medium is obtained by collecting the cell culture medium. The invention also relates to a conditioned medium obtained or obtainable by the producing method, a composition thereof and uses thereof.
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
5.
Method of isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord, a mesenchymal stem cell population isolated from the amniotic membrane of the umbilical cord and a cell culture medium for isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord
The present invention relates to a method of cryopreserving a mesenchymal stem cell population, the method comprising: cultivating umbilical cord tissue in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum) to provide outgrowth of mesenchymal stem cells present in the amniotic membrane of the umbilical cord; isolating the mesenchymal stem cell population by collecting the outgrown mesenchymal stem cells; and placing the isolated mesenchymal stem cell population in cryopreserved storage. The invention also relates to a cryopreserved mesenchymal stem population of the amniotic membrane of the umbilical cord.
The invention relates to a method of generating an induced pluripotent stem cell. The method of the disclosure comprises expressing exogenous nucleic acids encoding the proteins OCT3/4, SOX2, KLF4, LIN28 and L-MYC and the p53-shRNA in a stem cell of the amniotic membrane of the umbilical cord under conditions suitable to reprogram the stem cell, thereby generating the induced pluripotent stem cell. The present invention also refer to an induced pluripotent stem cell population obtainable by the method and an induced pluripotent stem cell population obtained by the method. Further, a pharmaceutical composition comprising the induced pluripotent stem cell of the present invention is concerned. The present invention also relates to a method of differentiating the induced pluripotent stem cell of this invention. In addition, a pharmaceutical composition comprising a differentiated induced pluripotent stem cell obtained by the method is also concerned. Further, the present invention concerns a method of treating a congenital or acquired degenerative disorder in a subject, comprising administering to a subject a target cell differentiated from pluripotent stem cell.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
7.
A METHOD OF DIFFERENTIATING AN INDUCED PLURIPOTENT STEM CELL INTO A RETINAL PIGMENT EPITHELIAL CELL, A RETINAL PIGMENT EPITHELIAL CELL AND METHODS OF USING THE RETINAL PIGMENT EPITHELIAL CELL
AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (Singapore)
CELLRESEARCH CORPORATION PTE. LTD (Singapore)
SINGAPORE HEALTH SERVICES PTE LTD (Singapore)
Inventor
Su, Xinyi
Kakkad, Regha
Bhargava, Mayuri
Yang, Binxia
Hunziker, Walter
Liu, Zengping
Wang, Haofei
Parikh, Bhav Harshad
Chen, Qingfeng
Lai, Fritz, Shien Choong
Lim, Kah Leong
Phan, Toan Thang
Abstract
The present invention relates to a method of differentiating an induced pluripotent stem cell into a retinal pigment epithelial cell. Additionally, the present invention relates to a retinal pigment epithelial cell culture obtainable by the differentiation method and a retinal pigment epithelial cell culture obtained by the differentiation method. In addition, the present invention concerns a retinal pigment epithelium consisting of or comprising a retinal pigment epithelial cell culture obtainable or obtained by the differentiation method. The present invention also relates to a pharmaceutical composition comprising a retinal pigment epithelial cell culture obtained by the differentiation method. The present invention concerns a method of treating a retinal degenerative disease in a subject, comprising administering to a subject a retinal pigment epithelial cell differentiated from the induced pluripotent stem cell by the method. Finally, the present invention also refers to an in vivo method of detecting the survival rate of a retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in a subject and an in vitro method of determining the immunogenicity of said retinal pigment epithelial cell differentiated from an induced pluripotent stem cell by the defined method in said subject, to whom said differentiated RPE cell has been pre-delivered.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Cosmetics; cosmetic preparations for skin care; cosmetic
creams; hair lotions; preparations for cosmetic hair
treatments; lotions for cosmetic purposes; cosmetic kits;
facial beauty masks; moisturising body lotions; skin
whitening creams; creams (non-medicated -) for the eyes;
skin whitening preparations [cosmetic]; facial serum for
cosmetic use; skin calming serums; skin relief serum
[cosmetic]; hair care serum; sun protection preparations;
sunscreen creams; suncare lotions; skin lotions; body
lotions; beauty lotions; face lotions; beauty gels; face
gels; body gels; eye gels; skin creams; body creams; face
creams; beauty creams; day creams; night creams; hand
creams. Pharmaceutical and veterinary preparations; pharmacological
preparations for skin care, in particular medicated skin
creams, medicated skin lotions, or skin calming serum
[medicated]; pharmaceutical preparation for treatment of
skin diseases, in particular pharmaceutical preparations for
treatment of rosacea, treatment of psoriasis, treatment of
eczema, treatment of dermatitis, treatment of topical
steroid withdrawal syndrome, treatment of epidermolysis
bullosa, or treatment of skin damage caused by fragile skin;
hair growth preparations (medicinal -); hair growth
stimulants; hair thickening preparations (medicinal -); hair
regeneration preparations (medicinal -); sanitary
preparations for medical purposes; plasters, materials for
dressings.
10.
Method of transporting mesenchymal stem cells by means of a transporting solution and a method of administering stem cells to wounds
The present invention relates to a method of transporting a stem cell population, the method comprising transporting the stem cell population contacted with a liquid carrier. In addition, the present invention concerns a method of treating a subject having a disease, the method comprising topically administering a defined mesenchymal stem cell population to the subject, wherein the mesenchymal stem cell population is administered within about 96 hours from the time point the mesenchymal stem cell population has been harvested. Also concerned is a unit dosage comprising about 20 million cells, of about 15 million cells, of about 10 million cells, of about 5 million cells, of about 4 million cells, of about 3 million cells, of about 2 million cells, of about 1 million cells, of about 0.5 million cells, of about 0.25 million cells or of less than 0.25 million cells of a defined mesenchymal stem cell population.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Cosmetics; cosmetic preparations for skin care; cosmetic creams; hair lotions; lotions for cosmetic purposes; facial beauty masks; moisturising body lotions; skin whitening creams; eye creams; skin whitening preparations; sunscreen creams; suncare lotions; skin lotions; body lotions; beauty lotions; beauty gels; eye gels; skin creams; body creams; face creams; beauty creams; night creams; hand creams Pharmaceutical preparations for treating skin conditions, namely, medicated skin care preparations being creams, lotions, and skin calming serums; pharmaceutical preparations for treatment of skin diseases, namely, rosacea, psoriasis, eczema, dermatitis, topical steroid withdrawal syndrome, epidermolysis bullosa, and treatment of skin damage caused by fragile skin; hair growth stimulants; sanitary preparations for medical purposes; plasters being medical dressings * ; all of the foregoing excluding pharmaceutical preparations for the
treatment of xerostomia *
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and veterinary preparations for treating wounds, eczema, skin diseases, atopic dermatitis, arthritic diseases, cardiac diseases, corneal diseases, liver diseases, genetic diseases, neuronal diseases, bone diseases, and cartilage diseases; Sanitary preparations for medical purposes; Medical plasters, materials for medical or surgical dressings, namely, gauzes and wadding
14.
A METHOD OF GENERATING AN INDUCED PLURIPOTENT STEM CELL, AN INDUCED PLURIPOTENT STEM CELL AND METHODS OF USING THE INDUCED PLURIPOTENT STEM CELL
OCT3/4, SOX2, KLF4, LIN28 L-MYCp53-shRNAp53-shRNA in a stem cell of the amniotic membrane of the umbilical cord under conditions suitable to reprogram the stem cell, thereby generating the induced pluripotent stem cell. The present invention also refer to an induced pluripotent stem cell population obtainable by the method and an induced pluripotent stem cell population obtained by the method. Further, a pharmaceutical composition comprising the induced pluripotent stem cell of the present invention is concerned. The present invention also relates to a method of differentiating the induced pluripotent stem cell of this invention. In addition, a pharmaceutical composition comprising a differentiated induced pluripotent stem cell obtained by the method is also concerned. Further, the present invention concerns a method of treating a congenital or acquired degenerative disorder in a subject, comprising administering to a subject a target cell differentiated from pluripotent stem cell.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
15.
ISOLATION AND CULTIVATION OF STEM/PROGENITOR CELLS FROM THE AMNIOTIC MEMBRANE OF UMBILICAL CORD AND USES OF CELLS DIFFERENTIATED THEREFROM
The present invention relates to a method of promoting skin rejuvenation in a subject. The method comprises administering to the subject an effective amount of a cellular extract of epithelial or mesenchymal stem/progenitor cells isolated from the amniotic membrane of the umbilical cord, wherein the cellular extract contains growth factors and peptides and is in the form of a supernatant into which the epithelial or mesenchymal stem/progenitor cells secrete the growth factors and peptides.
The present invention relates to a method of inducing or improving wound healing properties of a mesenchymal stem cell population, the method comprising cultivating the mesenchymal stem cell population in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population, wherein at least about 90% or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.
Method of isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord, a mesenchymal stem cell population isolated from the amniotic membrane of the umbilical cord and a cell culture medium for isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord
The present invention relates to a method of isolating a mesenchymal stem cell population from the amniotic membrane of the umbilical cord, the method comprising cultivating umbilical cord tissue in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population isolated from the amniotic membrane of the umbilical cord, wherein at least about 90% or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.
A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
18.
METHOD OF ASSESSING WOUND HEALING POTENCY OF A MESENCHYMAL STEM POPULATION AND RELATED METHODS OF SELECTING MESENCHYMAL STEM CELLS AND IDENTIFYING TISSUE AS STARTING MATERIAL FOR PRODUCING A MESENCHYMAL STEM CELL POPULATION
The present invention relates to a method of assessing the wound healing potency of a mesenchymal stem cell population. In addition, the present invention concerns a method of selecting a mesenchymal stem cell population for producing a stem cell population under cGMP conditions and a method of selecting a mesenchymal stem cell population for producing a stem cell population for subsequent pharmaceutical administration. Further, the present invention relates to a method of selecting a mesenchymal stem cell population for generating a master cell bank and to a method of identifying a tissue suitable as starting material for producing a mesenchymal stem cell population for pharmaceutical use.
G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
19.
A METHOD OF ASSESSING WOUND HEALING POTENCY OF A MESENCHYMAL STEM POPULATION AND RELATED METHODS OF SELECTING MESENCHYMAL STEM CELLS AND IDENTIFYING TISSUE AS STARTING MATERIAL FOR PRODUCING A MESENCHYMAL STEM CELL POPULATION
The present invention relates to a method of assessing the wound healing potency of a mesenchymal stem cell (MSC) population. In addition, the present invention concerns a method of selecting a MSC for producing a stem cell population under cGMP conditions, a method of selecting a MSC population for producing a stem cell population for subsequent pharmaceutical administration. Further the present invention relates to a method of selecting a MSC population for generating a master cell bank and a method for identifying a tissue suitable as starting material for producing a MSC for pharmaceutical use. Said methods comprise determining in a medium the level of at least two proteins selected from the group consisting of Angiopoietin 1 (Ang-1), Transforming Growth Factor β (TGF-β), Vascular Endothelial Growth Factor (VEGF) and Hepatocyte Growth Factor (HGF) secreted in a medium by the MSC.
The disclosure relates to a mesenchymal stem cell storing or transport formulation, a method of preparing and using said formulation. It also includes a method of treating a subject having a disease such as a wound by topically administering mesenchymal stem cells that have been stored or transported in the storing or transport formulation. Also concerned is a unit dosage of the mesenchymal stem cells. In the preferred embodiment, the formulation comprises HypoThermosol®, human serum albumin and Plasmalyte.
The present invention relates to a method of transporting a stem cell population, the method comprising transporting the stem cell population contacted with a liquid carrier. In the preferred embodiment, the liquid carrier is Hypothermosol and comprises Trolox e.g. Hypothermosol-FRS. In addition, the present invention concerns a method of treating a subject having a disease such as a wound, the method comprising topically administering a defined mesenchymal stem cell population to the subject, wherein the mesenchymal stem cell population is administered within about 96 hours from the time point the mesenchymal stem cell population has been harvested. Also concerned is a unit dosage comprising the defined mesenchymal stem cell population such as from the amniotic membrane of the umbilical cord, wherein at least 90% of the cells express each of CD73, CD90 and CD105.
The present invention relates to a method of inducing or improving wound healing properties of a mesenchymal stem cell population, the method comprising cultivating the mesenchymal stem cell population in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population, wherein at least about 90 % or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.
The present invention relates to a method of transporting a stem cell population, the method comprising transporting the stem cell population contacted with a liquid carrier. In the preferred embodiment, the carrier comprises DMEM, F12, M171 and FBS. In addition, the present invention concerns a method of treating a subject having a disease such as a wound, the method comprising topically administering a defined mesenchymal stem cell population to the subject, wherein the mesenchymal stem cell population is administered within about 96 hours from the time point the mesenchymal stem cell population has been harvested. Also concerned is a unit dosage comprising the defined mesenchymal stem cell population such as from the amniotic membrane of the umbilical cord, wherein at least 90% of the cells express each of CD73, CD90 and CD105.
The present invention relates to a method of transporting a stem cell population, the method comprising transporting the stem cell population contacted with a liquid carrier. In addition, the present invention concerns a method of treating a subject having a disease, the method comprising topically administering a defined mesenchymal stem cell population to the subject, wherein the mesenchymal stem cell population is administered within about 96 hours from the time point the mesenchymal stem cell population has been harvested. Also concerned is a unit dosage comprising about 20 million cells, of about 15 million cells, of about 10 million cells, of about 5 million cells, of about 4 million cells, of about 3 million cells, of about 2 million cells, of about 1 million cells, of about 0.5 million cells, of about 0.25 million cells or of less than 0.25 million cells of a defined mesenchymal stem cell population.
A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
A61K 9/00 - Medicinal preparations characterised by special physical form
25.
USE OF AN ESSENTIALLY PURE MESENCHYMAL STEM CELL POPULATION OF THE AMNIOTIC MEMBRANE OF UMBILICAL CORD FOR GENERATING A MAMMALIAN STEM CELL CARRYING A TRANSGENE
The present invention relates to a method of generating a transgenic mesenchymal stem cell population carrying a transgene, a transgenic mesenchymal stem cell (MSC) population obtained by or obtainable by means of enzyme mediated integration, a pharmaceutical composition and uses of the transgenic MSC population in particular for gene therapy. Also claimed are methods of treating a disease or disorder comprising administering the transgenic MSC population or a pharmaceutical composition thereof to a subject in need. In one example, the transgenic MSC population is obtained by zinc-finger (ZFN)-mediated insertion of factor VIII DNA into the AAVS1 locus of MSCs isolated from the amniotic membrane of the umbilical cord.
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Scientific and industrial research in the field of
biochemistry or pharmaceuticals, in particular research in
the field of regenerative medicine, research in the field of
tissue repair and regeneration, research in the field of
wound healing, research in the field of metabolic diseases,
research in the field of degenerative disease, research in
the field of cardiovascular diseases, research relating to
pharmaceutical uses of stem cells, in particular
pharmaceutical uses of stem cells isolated from the amniotic
membrane of umbilical cord and pharmaceutical uses of
conditioned media derived from cultivation of stem cells
isolated from the amniotic membrane of umbilical cord;
services of a biochemical or pharmaceutical laboratory. Blood bank services; medical services relating to
processing, testing and analysis of cord tissue; medical
services relating to isolation, processing, testing,
proliferation and analysis of stem cells, in particular stem
cells of the amniotic membrane of umbilical cord; providing
advice relating to all of the aforesaid.
28.
Method of isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord, a mesenchymal stem cell population isolated from the amniotic membrane of the umbilical cord and a cell culture medium for isolating mesenchymal stem cells from the amniotic membrane of the umbilical cord
The present invention relates to a method of isolating a mesenchymal stem cell population from the amniotic membrane of the umbilical cord, the method comprising cultivating umbilical cord tissue in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population isolated from the amniotic membrane of the umbilical cord, wherein at least about 90% or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.
The present invention relates to a method of promoting skin rejuvenation in a subject. The method comprises administering to the subject an effective amount of a cellular extract of epithelial or mesenchymal stem/progenitor cells isolated from the amniotic membrane of the umbilical cord, wherein the cellular extract contains growth factors and peptides and is in the form of a supernatant into which the epithelial or mesenchymal stem/progenitor cells secrete the growth factors and peptides.
The present invention relates to a method of isolating a mesenchymal stem cell population from the amniotic membrane of the umbilical cord, the method comprising cultivating umbilical cord tissue in a culture medium comprising DMEM (Dulbecco's modified eagle medium), F12 (Ham's F12 Medium), M171 (Medium 171) and FBS (Fetal Bovine Serum). The invention also relates to a mesenchymal stem population isolated from the amniotic membrane of the umbilical cord, wherein at least about 90 % or more cells of the stem cell population express each of the following markers: CD73, CD90 and CD105 and lack expression of the following markers: CD34, CD45 and HLA-DR. The invention also relates to a pharmaceutical composition of this mesenchymal stem population.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Blood bank services; testing and analysis of umbilical cord tissue with respect to the viability and proliferation of stem cells contained in the umbilical cord tissue for diagnostic or treatment purposes; isolation of stem cells, in particular stem cells of the amniotic membrane of umbilical cord, for treatment purposes; testing and analysis of stem cells, in particular stem cells of the amniotic membrane of umbilical cord, with respect to the expression of stem cell biomarkers for diagnostic or treatment purposes; providing advice relating to all of the aforesaid
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
Goods & Services
cosmetics; cosmetic preparations for skin care; cosmetic creams; hair lotions; lotions for cosmetic purposes; cosmetic kits; facial beauty masks; moisturising body lotions; skin whitening creams; creams (non-medicated -) for the eyes.
34.
A METHOD OF GENERATING A MAMMALIAN STEM CELL CARRYING A TRANSGENE, A MAMMALIAN STEM CELL GENERATED BY THE METHOD AND PHARMACEUTICALS USES OF THE MAMMALIAN STEM CELL
The present invention relates to a method of generating a mammalian stem cell carrying a transgene, the method comprising inserting a transgene into the genome of the mammalian stem cell by means of zinc finger nuclease (ZFN) mediated integration. The invention also relates to a mammalian cell obtained by this method as well as to a pharmaceutical composition containing such a mammalian stem cell. The invention further relates to a method of treating a patient having a disease, the method comprising administering the patient a mammalian stem cell of the invention. In illustrative embodiments the disease is a disease associated with a deficiency of a gene or deficiency of the expression of the gene such as a gene selected from the group consisting of a gene encoding a blood coagulation factor and a gene encoding a protein hormone secreted by an endocrine gland. The blood coagulation factor may be selected from the group consisting of factor VII, factor VIII and factor IX and the disease may be any form of hemophilia, i.e. hemophilia A, hemophilia B or hemophilia C.
The present invention relates to the generation of a chondrocyte using mesenchymal stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such chondrocytes.
The present invention relates to a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The isolated stem cell cells can have embryonic stem cell-like properties and can be used for various therapeutic purposes. In one embodiment, the invention relates to the isolation and cultivation of stem cells such as epithelial and/or mesenchymal stem/progenitor cells under conditions allowing the cells to undergo mitotic expansion. Furthermore, the invention is directed to a method for the differentiation of the isolated stem/progenitor cells into epithelial and/or mesenchymal cells.
The present invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Soaps; cosmetics, hair lotions. Pharmaceutical and veterinary preparations; sanitary
preparations for medical purposes; plasters, materials for
dressings.
03 - Cosmetics and toiletries; cleaning, bleaching, polishing and abrasive preparations
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
[ Bath soaps; bar soaps; ] cosmetics [ ; hair lotions ] [ Pharmaceutical and veterinary preparations for treating skin conditions; sanitary preparations for medical purposes; medical plasters; materials for medical dressings ]
46.
Skin equivalents derived from umbilical cord mesenchymal stem/progenitor cells and umbilical cord epithelial stem/progenitor cells
The present invention relates to a skin equivalent and a method for producing the same, wherein the skin equivalent comprises a scaffold and stem/progenitor cells isolated from the amniotic membrane of umbilical cord. These stem/progenitor cells may be mesenchymal (UCMC) and/or epithelial (UCEC) stem cells, which may then be further differentiated to fibroblast and keratinocytes. Further described is a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The invention also refers to therapeutic uses of these skin equivalents. Another aspect of the invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells. In yet another aspect, the invention relates to a method for generating an insulin-producing cell using stem/progenitor cells isolated from the amniotic membrane of umbilical cord and therapeutic uses thereof. The invention further refers to a method of treating a bone or cartilage disorder using UCMC. Furthermore, the invention refers to a method of generating a dopamin and tyrosin hydroxylase as well as a HLA-G and hepatocytes using UCMC and/or UCEC. The present invention also refers to a method of inducing proliferation of aged keratinocytes using UCMC.
C12N 15/00 - Mutation or genetic engineeringDNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purificationUse of hosts therefor
47.
ISOLATION AND CULTIVATION OF STEM/PROGENITOR CELLS FROM THE AMNIOTIC MEMBRANE OF UMBILICAL CORD AND USES OF CELLS DIFFERENTIATED THEREFROM
The present invention relates to a skin equivalent and a method for producing the same, wherein the skin equivalent comprises a scaffold and stem/progenitor cells isolated from the amniotic membrane of umbilical cord. These stem/progenitor cells may be mesenchymal (UCMC) and/or epithelial (UCEC) stem cells, which may then be further differentiated to fibroblast and keratinocytes. Further described is a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The invention also refers to therapeutic uses of these skin equivalents. Another aspect of the invention relates to the generation of a mucin-producing cell using stem/progenitor cells obtained from the amniotic membrane of umbilical cord and therapeutic uses of such mucin-producing cells. In yet another aspect, the invention relates to a method for generating an insulin-producing cell using stem/progenitor cells isolated from the amniotic membrane of umbilical cord and therapeutic uses thereof. The invention further refers to a method of treating a bone or cartilage disorder using UCMC. Furthermore, the invention refers to a method of generating a dopamin and tyrosin hydroxylase as well as a HLA-G and hepatocytes using UCMC and/or UCEC. The present invention also refers to a method of inducing proliferation of aged keratinocytes using UCMC.
The present invention relates to a method for isolating stem/progenitor cells from the amniotic membrane of umbilical cord, wherein the method comprises separating the amniotic membrane from the other components of the umbilical cord in vitro, culturing the amniotic membrane tissue under conditions allowing cell proliferation, and isolating the stem/progenitor cells from the tissue cultures. The isolated stem cell cells can have embryonic stem cell-like properties and can be used for various therapeutic purposes. In one embodiment, the invention relates to the isolation and cultivation of stem cells such as epithelial and/or mesenchymal stem/progenitor cells under conditions allowing the cells to undergo mitotic expansion. Furthermore, the invention is directed to a method for the differentiation of the isolated stem/progenitor cells into epithelial and/or mesenchymal cells.
